In conclusion, we have developed a glioma-specific gene therapy system that expresses the HSV-tk suicide gene under direct transcriptional control of the FOS promoter, and have validated the therapeutic effects of this system in glioma in vitro and in vivo. The gene discussed is TKT; the disease is glioma.